$4.13
At close: Apr 24 EDT
$4.07
-0.06-1.45%
Pre-Market: 5:00 PM EDT
Comments
Loading...
Y-mAbs Therapeutics Analyst Ratings and Price Targets | NASDAQ:YMAB | Benzinga
Y-mAbs Therapeutics Inc has a consensus price target of $18.07 based on the ratings of 16 analysts. The high is $26 issued by Canaccord Genuity on August 13, 2024. The low is $7 issued by Morgan Stanley on March 5, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., B of A Securities, and Truist Securities on March 21, 2025, March 5, 2025, and March 5, 2025, respectively. With an average price target of $14 between HC Wainwright & Co., B of A Securities, and Truist Securities, there's an implied 243.98% upside for Y-mAbs Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
B of A Securities
Truist Securities
Morgan Stanley
Brookline Capital
1calculated from analyst ratings
Analyst Ratings for Y-mAbs Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/21/2025 | Buy Now | 194.84% | HC Wainwright & Co. | Robert Burns42% | $22 → $12 | Maintains | Buy | Get Alert |
| 03/05/2025 | Buy Now | 194.84% | B of A Securities | Alec Stranahan33% | $14 → $12 | Maintains | Neutral | Get Alert |
| 03/05/2025 | Buy Now | 342.26% | Truist Securities | Nicole Germino43% | $21 → $18 | Maintains | Buy | Get Alert |
| 03/05/2025 | Buy Now | 71.99% | Morgan Stanley | Michael Ulz59% | $11 → $7 | Maintains | Underweight | Get Alert |
| 01/13/2025 | Buy Now | 440.54% | HC Wainwright & Co. | Robert Burns42% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | — | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | 317.69% | Brookline Capital | Kemp Dolliver27% | → $17 | Initiates | → Buy | Get Alert |
| 11/18/2024 | Buy Now | 465.11% | Oppenheimer | Jeff Jones33% | → $23 | Initiates | → Outperform | Get Alert |
| 11/15/2024 | Buy Now | 440.54% | HC Wainwright & Co. | Robert Burns42% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 09/10/2024 | Buy Now | 465.11% | Wedbush | David Nierengarten62% | $23 → $23 | Reiterates | Outperform → Outperform | Get Alert |
| 09/09/2024 | Buy Now | 391.4% | Cantor Fitzgerald | Li Watsek40% | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 08/16/2024 | Buy Now | 391.4% | Cantor Fitzgerald | Li Watsek40% | → $20 | Initiates | → Overweight | Get Alert |
| 08/13/2024 | Buy Now | 538.82% | Canaccord Genuity | Bill Maughan19% | $26 → $26 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 170.27% | Morgan Stanley | Michael Ulz59% | $12 → $11 | Maintains | Underweight | Get Alert |
| 08/13/2024 | Buy Now | 440.54% | HC Wainwright & Co. | Robert Burns42% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 514.25% | BMO Capital | Etzer Darout48% | $26 → $25 | Maintains | Outperform | Get Alert |
| 07/11/2024 | Buy Now | 465.11% | Jones Trading | Justin Walsh43% | → $23 | Initiates | → Buy | Get Alert |
| 06/28/2024 | Buy Now | 415.97% | Truist Securities | Nicole Germino43% | → $21 | Initiates | → Buy | Get Alert |
| 05/13/2024 | Buy Now | 440.54% | HC Wainwright & Co. | Robert Burns42% | $21 → $22 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 440.54% | HC Wainwright & Co. | Robert Burns42% | $21 → $22 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 538.82% | Canaccord Genuity | Bill Maughan19% | $22 → $26 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 538.82% | BMO Capital | Etzer Darout48% | $16 → $26 | Maintains | Outperform | Get Alert |
| 02/20/2024 | Buy Now | 415.97% | HC Wainwright & Co. | Robert Burns42% | $11 → $21 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 170.27% | HC Wainwright & Co. | Robert Burns42% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | 71.99% | JP Morgan | Tessa Romero59% | $8 → $7 | Maintains | Underweight | Get Alert |
| 08/14/2023 | Buy Now | 22.85% | Morgan Stanley | Michael Ulz59% | $7 → $5 | Maintains | Underweight | Get Alert |
| 08/14/2023 | Buy Now | 170.27% | HC Wainwright & Co. | Robert Burns42% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | Buy Now | 440.54% | Canaccord Genuity | William Plovanic56% | $21 → $22 | Maintains | Buy | Get Alert |
| 06/07/2023 | Buy Now | 415.97% | Canaccord Genuity | William Plovanic56% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 194.84% | B of A Securities | Alec Stranahan33% | $6 → $12 | Maintains | Neutral | Get Alert |
| 05/10/2023 | Buy Now | 71.99% | Morgan Stanley | Michael Ulz59% | $4 → $7 | Maintains | Underweight | Get Alert |
| 05/10/2023 | Buy Now | 219.41% | Wedbush | David Nierengarten62% | $5 → $13 | Upgrade | Neutral → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 415.97% | Canaccord Genuity | William Plovanic56% | $18 → $21 | Maintains | Buy | Get Alert |
| 04/04/2023 | Buy Now | 170.27% | HC Wainwright & Co. | Robert Burns42% | $19 → $11 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | — | Guggenheim | Etzer Darout48% | — | Downgrade | Buy → Neutral | Get Alert |
| 04/01/2023 | Buy Now | 47.42% | B of A Securities | Alec Stranahan33% | → $6 | Maintains | Neutral | Get Alert |
| 03/31/2023 | Buy Now | 342.26% | Canaccord Genuity | William Maughan71% | $20 → $18 | Maintains | Buy | Get Alert |
| 01/30/2023 | Buy Now | 219.41% | BMO Capital | Etzer Darout48% | $12 → $13 | Maintains | Outperform | Get Alert |
| 01/27/2023 | Buy Now | — | Morgan Stanley | Michael Ulz59% | — | Downgrade | Equal-Weight → Underweight | Get Alert |
| 01/05/2023 | Buy Now | — | Cowen & Co. | Joseph Thome28% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 12/15/2022 | Buy Now | 47.42% | B of A Securities | Alec Stranahan33% | $5 → $6 | Maintains | Neutral | Get Alert |
| 12/02/2022 | Buy Now | 22.85% | B of A Securities | Alec Stranahan33% | $23 → $5 | Downgrade | Buy → Neutral | Get Alert |
| 11/01/2022 | Buy Now | 194.84% | BMO Capital | Etzer Darout48% | $29 → $12 | Maintains | Outperform | Get Alert |
| 10/31/2022 | Buy Now | 563.39% | Canaccord Genuity | William Maughan71% | $35 → $27 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | 96.56% | Morgan Stanley | Michael Ulz59% | $17 → $8 | Maintains | Equal-Weight | Get Alert |
| 10/31/2022 | Buy Now | 47.42% | Wedbush | David Nierengarten62% | → $6 | Downgrade | Outperform → Neutral | Get Alert |
| 10/31/2022 | Buy Now | 366.83% | HC Wainwright & Co. | Robert Burns42% | $63 → $19 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | 71.99% | JP Morgan | Tessa Romero59% | $16 → $7 | Downgrade | Neutral → Underweight | Get Alert |
| 09/09/2022 | Buy Now | 317.69% | Morgan Stanley | Michael Ulz59% | $15 → $17 | Maintains | Equal-Weight | Get Alert |
| 06/24/2022 | Buy Now | 563.39% | BMO Capital | Etzer Darout48% | → $27 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Y-mAbs Therapeutics (YMAB) stock?
The latest price target for Y-mAbs Therapeutics (NASDAQ:YMAB) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $12.00 expecting YMAB to rise to within 12 months (a possible 194.84% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Y-mAbs Therapeutics (YMAB)?
The latest analyst rating for Y-mAbs Therapeutics (NASDAQ:YMAB) was provided by HC Wainwright & Co., and Y-mAbs Therapeutics maintained their buy rating.
When was the last upgrade for Y-mAbs Therapeutics (YMAB)?
The last upgrade for Y-mAbs Therapeutics Inc happened on May 10, 2023 when Wedbush raised their price target to $13. Wedbush previously had a neutral for Y-mAbs Therapeutics Inc.
When was the last downgrade for Y-mAbs Therapeutics (YMAB)?
The last downgrade for Y-mAbs Therapeutics Inc happened on April 3, 2023 when Guggenheim changed their price target from N/A to N/A for Y-mAbs Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Y-mAbs Therapeutics (YMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.
Is the Analyst Rating Y-mAbs Therapeutics (YMAB) correct?
While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a maintained with a price target of $22.00 to $12.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $4.07, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
